Researchers are exploring using glucagon-like peptide-1 receptor agonists (GLP-1 drugs such as Wegovy, Mounjaro, Zepbound, Trulicity, and Ozempic) for substance use disorder (SUD) and alcohol use disorder (AUD) treatment. These medications are being used to manage weight loss and diabetes, although none are FDA-approved for SUD/AUD, and some treatment providers are using them to address cravings. Panelists will discuss the possibilities of these drugs to improve patient outcomes, the opportunity to expand services, the reimbursement landscape, concerns about diversion and misuse, and other factors executives should consider.

This webinar has concluded. To access the on demand link, please click here. 

In this live webinar, hear from experts featured in TCIV’s executive report as they explore the emerging use of GLP-1 medications like Ozempic and Wegovy in addiction treatment. Learn how treatment centers are integrating these medications, what early results show, and what executives need to know about clinical potential, safety, and coverage.

This is a non-CME event. By registering for this program, you consent to share your registration information with the program's sponsor.